Related Experiment Video

Updated: Aug 11, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

The application of epigenetic modifiers on the treatment of prostate and bladder cancer

Zhengwang Zhang1, Jose Karam, Eugene Frenkel

  • 1Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA.

Urologic Oncology
|March 8, 2006
PubMed

Insights

Epigenetic gene silencing impacts prostate cancer and bladder transitional cell carcinoma (TCC). Epigenetic modifiers offer new therapeutic strategies, potentially enhancing treatments for advanced or refractory cases.

Area of Science:

  • Oncology
  • Epigenetics
  • Urogenital Malignancies

Background:

  • Prostate cancer and transitional cell carcinoma (TCC) are common male urogenital system cancers.
  • Epigenetic gene silencing, especially of tumor suppressor genes, is a key area in cancer research.
  • Epigenetic alterations play a significant role in the development and progression of these malignancies.

Purpose of the Study:

  • To review current knowledge of epigenetic events in prostate cancer and TCC.
  • To discuss the potential clinical implications of epigenetic modifications in these cancers.
  • To explore novel therapeutic avenues targeting epigenetic pathways.

Main Methods:

  • Review of existing literature on epigenetic alterations in prostate cancer and TCC.
  • Analysis of the role of epigenetic modifiers like DNA methyltransferase and histone deacetylase inhibitors.
  • Discussion of potential combination therapies involving epigenetic agents.

Main Results:

  • Epigenetic silencing contributes to the pathogenesis of prostate cancer and TCC.
  • Epigenetic modifiers can restore gene expression and modify cancer cell phenotype.
  • Combination regimens with epigenetic modifiers may improve outcomes for refractory or metastatic disease.

Conclusions:

  • Epigenetic modifications represent a promising therapeutic target for prostate cancer and TCC.
  • Epigenetic modifiers offer a new treatment modality for these urogenital malignancies.
  • Further research into combination therapies holds potential for improving patient outcomes.

More Related Videos

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...